| FATE THERAPEUTICS DL-,001 |
| USA |
| Gesundheit |
| US31189P1021 / A1W50M |
| F6T (Frankfurt) / FATE (NASDAQ) |
| FRA:F6T, ETR:F6T, F6T:GR, NASDAQ:FATE |
| - |
| https://fatetherapeutics... |
|
Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies using induced pluripotent stem cell (iPSC) technology to treat cancer and autoimmune diseases. The company's pipeline includes FT81..
>Volltext.. |
| 298.73 Mio. EUR |
| 213.99 Mio. EUR |
| 5.52 Mio. EUR |
| -111.03 Mio. EUR |
| -113.63 Mio. EUR |
| -0.95 EUR |
| 67.16 Mio. EUR |
| 34.61 Mio. EUR |
| -90.18 Mio. EUR |
| 5.7 |
| -55.65% |
| 30.84% |
| - |
| - |
| - |
| - |
| FATE THERAPEUTICS, FATE THERAPEUTIC |
| 10.07.26 |